Humulin S (Soluble) (Insulin Human (Rdna))

Humulin S (Soluble) is indicated for the management of blood glucose in both adult and pediatric patients with diabetes, and it may be incorporated into various insulin regimens.

• Type 1 diabetes mellitus (insulin‑dependent)
• Type 2 diabetes mellitus when oral agents are insufficient
• To control hyperglycemia during meals (prandial insulin)
• As part of basal‑bolus insulin regimens
• For use in hospitalized patients requiring rapid glucose control
• For use in insulin pump therapy when rapid‑acting insulin is required

• Humulin S (Soluble) contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑kinase/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and suppressing hepatic gluconeogenesis. This effect lowers circulating glucose levels and assists in maintaining target glycemic ranges.

Adverse reactions to Humulin S (Soluble) are reported in clinical practice and can vary in frequency and severity.

Common

• Mild to moderate hypoglycemia, characterized by shakiness, sweating, or dizziness.
• Pain, redness, or swelling at the injection site.
• Localized lipohypertrophy or lipoatrophy with repeated use.
• Gradual weight increase associated with improved glycemic control.

Serious

• Severe hypoglycemia with confusion, seizures, or loss of consciousness.
• Immediate‑type allergic reactions, including hives, swelling of the face or throat, and anaphylaxis.
• Fluid retention leading to peripheral edema or worsening heart failure.
• Marked decrease in serum potassium (hypokalemia) that may affect cardiac rhythm.

When prescribing Humulin S (Soluble), clinicians should consider several precautionary measures to ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during initiation, dose changes, or illness.
• Use lower initial doses in pediatric patients and in those with low body weight.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Review concomitant medications that affect glucose metabolism, such as glucocorticoids.
• Caution in pregnancy and lactation; benefits must outweigh potential risks.
• Avoid use in patients with known hypersensitivity to human insulin or excipients.

Humulin S (Soluble) may interact with other agents that influence glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• High‑dose beta‑blockers that mask hypoglycemia symptoms.
• MAO‑inhibitors combined with sympathomimetic agents causing unpredictable glucose changes.

Use with caution

• Oral hypoglycemic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose and require insulin dose increase.
• Thiazide diuretics, which can affect potassium balance and insulin sensitivity.
• Alcohol, especially in excess, which can cause delayed hypoglycemia.